CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

October 17, 2018

Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute:

Study: Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-NHL-006) for B-cell non-Hodgkin lymphoma

JCAR017 is an investigational CAR T-cell therapy that modifies a patient’s own T-cells to express proteins called CARs (chimeric antigen receptors), which help T-cells recognize tumor cells and go after them. A Phase I study of JCAR017 in people with aggressive forms of B-cell lymphoma found that it provided “a durable reduction or eradication of cancer,” including complete cancer eradication in just over half of the patients. Read more in Lymphoma News Today.

CAR T-cell therapy is a major research priority for the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center. Read more about JCAR017 in Immuno-Oncology News, and find out more about adoptive T-cell therapy research at Providence.

Providence is one of only two centers in the United States currently participating in this clinical trial. For more information or to enroll a patient, call our Clinical Research office at 503-215-2614. Call us early for consideration, before the patient receives a salvage therapy or stem cell transplant.

See more studies
New research studies are added frequently. Please visit our website to see all studies in all cancer types currently open at Providence Cancer Institute.